Journal of Clinical Oncology, Vol 10, 383-389, Copyright © 1992 by American Society of Clinical Oncology
Molecular and immunophenotypic characterization of AIDS-associated, Epstein-Barr virus-negative, polyclonal lymphoma
B Shiramizu, B Herndier, T Meeker, L Kaplan and M McGrath
Department of Pediatrics, University of California, San Francisco 94110.
PURPOSE: A molecular analysis of non-Hodgkin's lymphomas (NHLs) from
patients with AIDS was undertaken to determine the prevalence and
immunophenotype of polyclonal B-cell lymphoma. MATERIALS AND METHODS: DNA
was extracted from 40 diagnostic biopsy specimens obtained from patients
seen at University of California, San Francisco (UCSF) between 1986 and
1990. Clonality, infection with Epstein-Barr virus (EBV), and presence of a
rearranged c-myc gene were determined by Southern blot analysis. Lymphoma
immunophenotypes were determined by frozen-section immunohistochemical
analysis. RESULTS: The most prevalent genotype of lymphoma in this study
was that of polyclonal, EBV-negative tumors with no evidence of c-myc
rearrangement (14 of 40; 35%). Monoclonal, EBV- positive tumors with no
evidence of c-myc rearrangement comprised the second most prevalent class
(10 of 40; 25%), and polyclonal, EBV- positive tumors similar to those seen
in transplant patients were observed in only a small subset (three of 40;
8%) of specimens analyzed. The immunophenotype of B cells in the polyclonal
EBV-negative subset was equally divided into B-cell-predominant and
mixed-phenotype lymphomas, with the latter category containing numerous
infiltrating T cells. The B cells in each category were immunoglobulin
M-positive (IgM+), CD20+, CD21-. All but one of the polyclonal NHLs had
large-cell histology. CONCLUSIONS: EBV-negative, AIDS-associated,
polyclonal B- cell lymphoma appears to be a new class of human
immunodeficiency virus (HIV)-associated disease more prevalent in the
current study than any other molecular subclass. The absence of CD21, the
EBV receptor, may explain in part the absence of EBV within this polyclonal
B-cell population.